{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Akingbade D"],"funding":["NCI NIH HHS","National Institutes of Health"],"pagination":["454-61"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3285145"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(2)"],"pubmed_abstract":["Oxidative stress triggers DNA and lipid peroxidation, leading to the formation of electrophiles that react with DNA to form adducts. A product of this pathway, (3-(2'-deoxy-β-d-erythro-pentofuranosyl)-pyrimido[1,2-α]purine-10(3H)-one), or M(1)dG, is mutagenic in bacterial and mammalian cells and is repaired by the nucleotide excision repair pathway. In vivo, M(1)dG is oxidized to a primary metabolite, (3-(2-deoxy-β-d-erythro-pentofuranosyl)-pyrimido[1,2-α]purine-6,10(3H,5H)-dione, or 6-oxo-M(1)dG, which is excreted in urine, bile, and feces. We have developed a specific monoclonal antibody against 6-oxo-M(1)dG and have incorporated this antibody into a procedure for the immunoaffinity isolation of 6-oxo-M(1)dG from biological matrices. The purified analyte is quantified by LC-MS/MS using a"],"journal":["Chemical research in toxicology"],"pubmed_title":["Selection of monoclonal antibodies against 6-oxo-M(1)dG and their use in an LC-MS/MS assay for the presence of 6-oxo-M(1)dG in vivo."],"pmcid":["PMC3285145"],"funding_grant_id":["R37 CA087819"],"pubmed_authors":["Marnett LJ","Szekely J","Akingbade D","Carnahan R","Cooper T","Kingsley PJ","Shuck SC"],"additional_accession":[]},"is_claimable":false,"name":"Selection of monoclonal antibodies against 6-oxo-M(1)dG and their use in an LC-MS/MS assay for the presence of 6-oxo-M(1)dG in vivo.","description":"Oxidative stress triggers DNA and lipid peroxidation, leading to the formation of electrophiles that react with DNA to form adducts. A product of this pathway, (3-(2'-deoxy-β-d-erythro-pentofuranosyl)-pyrimido[1,2-α]purine-10(3H)-one), or M(1)dG, is mutagenic in bacterial and mammalian cells and is repaired by the nucleotide excision repair pathway. In vivo, M(1)dG is oxidized to a primary metabolite, (3-(2-deoxy-β-d-erythro-pentofuranosyl)-pyrimido[1,2-α]purine-6,10(3H,5H)-dione, or 6-oxo-M(1)dG, which is excreted in urine, bile, and feces. We have developed a specific monoclonal antibody against 6-oxo-M(1)dG and have incorporated this antibody into a procedure for the immunoaffinity isolation of 6-oxo-M(1)dG from biological matrices. The purified analyte is quantified by LC-MS/MS using a","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Feb","modification":"2025-06-01T03:32:40.065Z","creation":"2025-06-01T03:32:40.065Z"},"accession":"S-EPMC3285145","cross_references":{"pubmed":["22211372"],"doi":["10.1021/tx200494h"]}}